Kim E S, Cramer K D, Shreve A L, Sherman D H
Department of Microbiology, University of Minnesota, St. Paul 55108.
J Bacteriol. 1995 Mar;177(5):1202-7. doi: 10.1128/jb.177.5.1202-1207.1995.
Polyketides are an extensive class of secondary metabolites with diverse molecular structures and biological activities. A plasmid-based multicomponent polyketide synthase expression cassette was constructed using a subset of actinorhodin (act) biosynthetic genes (actI-orf1, actI-orf2, actI-orf3, actIII, actVII, and actIV) from Streptomyces coelicolor which specify the construction of the anthraquinone product aloesaponarin II, a molecule derived from acetyl coenzyme A and 7 malonyl coenzyme A extender units. This system was designed as an indicator pathway in Streptomyces parvulus to quantify polyketide product formation and to examine the functional significance of specific polyketide synthase components, including the act beta-ketoacyl synthase (beta-KS; encoded by actI-orf1 and actI-orf2) and the act cyclase/dehydrase (encoded by actVII-orf4). Site-directed mutagenesis of the putative active site Cys (to a Gln) in the actI-orf1 beta-KS product completely abrogated aloesaponarin II production. Changing the putative acyltransferase active-site Ser (to a Leu) located in the actI-orf1 beta-KS product led to significantly reduced but continued production of aloesaponarin II. Replacement of the expression cassette with one containing a mutant form of actI-orf2 gave no production of aloesaponarin II or any other detectable polyketide products. However, an expression cassette containing a mutant form of actVII-orf4 gave primarily mutactin with low-level production of aloesaponarin II.
聚酮化合物是一类广泛的次生代谢产物,具有多样的分子结构和生物活性。利用来自天蓝色链霉菌的放线紫红素(act)生物合成基因的一个子集(actI-orf1、actI-orf2、actI-orf3、actIII、actVII和actIV)构建了一个基于质粒的多组分聚酮合酶表达盒,这些基因决定了蒽醌产物芦荟皂苷元II的合成,芦荟皂苷元II是一种由乙酰辅酶A和7个丙二酰辅酶A延伸单位衍生而来的分子。该系统被设计为小链霉菌中的一个指示途径,用于量化聚酮化合物产物的形成,并研究特定聚酮合酶组分的功能意义,包括actβ-酮酰基合酶(β-KS;由actI-orf1和actI-orf2编码)和act环化酶/脱水酶(由actVII-orf4编码)。对actI-orf1β-KS产物中假定的活性位点半胱氨酸(突变为谷氨酰胺)进行定点诱变,完全消除了芦荟皂苷元II的产生。将actI-orf1β-KS产物中假定的酰基转移酶活性位点丝氨酸(突变为亮氨酸),导致芦荟皂苷元II的产量显著降低,但仍有持续产生。用含有actI-orf2突变形式的表达盒替换原表达盒,未产生芦荟皂苷元II或任何其他可检测到的聚酮化合物产物。然而,含有actVII-orf4突变形式的表达盒主要产生变构菌素,芦荟皂苷元II的产量较低。